Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...
Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...
1d
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...
Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with Bria-OTS, the company's novel ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback